NCT03062319View on ClinicalTrials.gov

Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis

PHASE4TerminatedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

April 6, 2017

Primary Completion Date

July 18, 2023

Study Completion Date

July 18, 2023

Conditions
Ischemic StrokeAtrial FibrillationAtherothrombosis
Interventions
DRUG

Oral Anticoagulant

warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban

DRUG

Antiplatelet Drug

aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol

Trial Locations (1)

540-0006

National Hospital Organization Osaka National Hospital, Osaka

Sponsors
All Listed Sponsors
collaborator

Network for Clinical Stroke Trials

UNKNOWN

collaborator

The BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program

UNKNOWN

lead

National Hospital Organization Osaka National Hospital

OTHER

NCT03062319 - Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis | Biotech Hunter | Biotech Hunter